The IPO removes immediate bankruptcy risk and funds ipsoprubart through its pivotal readout. Monitor SURPASS enrollment progress and any early efficacy signals from the single-arm trial design, as the external control comparator (COMPASS) introduces regulatory uncertainty.
Executive Summary
Electra Therapeutics priced its IPO of 23,333,334 shares at $15.00 per share, raising $350.0 million in gross proceeds ($325.5 million net before expenses). The offering resolves a going-concern doubt, extending the company's cash runway into 2029 to fund its lead candidate ipsoprubart through a Phase 2/3 registrational trial in sHLH and advance ELA822. The IPO provides a critical capital infusion for a pre-revenue biotech with promising Phase 1b data but significant clinical and regulatory execution risk ahead.
Key Financial Metrics
Key Facts
- IPO of 23,333,334 shares priced at $15.00 per share, raising $350,000,010 in gross proceeds.
- Net proceeds to Electra estimated at $325,500,009 before expenses; $319.9 million after estimated offering expenses.
- Underwriters granted a 30-day option to purchase up to an additional 3,500,000 shares.
- Shares to begin trading on Nasdaq under ticker ETRA, with delivery expected September 21, 2026.
- Pro forma as-adjusted cash, cash equivalents and marketable securities of $417.6 million, extending runway into 2029.
- Lead candidate ipsoprubart is in a global Phase 2/3 registrational trial (SURPASS) for sHLH, with enrollment completion expected in H2 2027.
- Company had a going-concern doubt prior to the IPO; accumulated deficit of $221.9 million as of June 30, 2026.
- Underwriters include Jefferies, TD Cowen, Evercore ISI, and Cantor.
Financial Impact
IPO raises $350.0 million at $15.00/share; net proceeds of ~$319.9 million extend cash runway into 2029, resolving near-term going-concern risk.
Risk Factors
- SURPASS is a single-arm, open-label trial relying on an external control (COMPASS); FDA may not accept the data for approval.
- Phase 1b data was based on only 12 frontline mHLH patients; larger registrational trial may fail to replicate results.
- No approved therapies for sHLH broadly; regulatory path is novel and uncertain.
- Company has no revenue, no approved products, and expects significant ongoing losses.
- CMO facility for drug product received an OAI classification from the FDA, posing manufacturing risk.
- 180-day lock-up expires; post-lock-up selling pressure from existing holders.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-395670 |
| Document: 0001193125-26-395670-index-headers.html | 0001193125-26-395670 |
| Document: 0001193125-26-395670-index.html | 0001193125-26-395670 |
| Document: 0001193125-26-395670.txt | 0001193125-26-395670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 27d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 28, 2026 27d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 25, 2026 4w ago | SC 13D | $11.32 $11.35 | ▲ +0.27% | ▲ +0.45% | $8.37 (−26.06%) |
Sep 23, 2026 4w ago | Insider Cluster | $11.82 $11.55 | ▼ −2.28% | ▼ −2.83% | $8.37 (−29.19%) |
Sep 21, 2026 4w ago | 3 | $13.62 $12.67 | ▼ −6.97% | ▼ −6.25% | $8.37 (−38.55%) |
Sep 18, 2026 5w ago | 424B4 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | EFFECT | $13.25 $13.92 | ▲ +5.06% | ▲ +3.51% | $8.37 (−36.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers